StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research report sent to investors on Friday morning. The brokerage issued a sell rating on the stock.
Oragenics Price Performance
Shares of Oragenics stock opened at $1.27 on Friday. The stock has a market capitalization of $7.09 million, a PE ratio of -0.15 and a beta of 0.50. Oragenics has a 52-week low of $0.86 and a 52-week high of $7.74. The business has a 50-day moving average price of $1.13.
Oragenics (NYSE:OGEN – Get Free Report) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.
Institutional Inflows and Outflows
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Recommended Stories
- Five stocks we like better than Oragenics
- What Are Dividends? Buy the Best Dividend Stocks
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- How to Read Stock Charts for Beginners
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- What is a Secondary Public Offering? What Investors Need to Know
- MarketBeat Week in Review – 8/26 – 8/30
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.